This inventor holds 2 USPTO granted patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2013-2014.
Company Filing History:
Years Active: 2013-2014
Title: William Trenkle: Innovator in Pharmaceutical Compounds
Introduction
William Trenkle is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological processes. With a total of 2 patents, Trenkle's work focuses on innovative methods to treat disorders related to deubiquitination.
Latest Patents
Trenkle's latest patents include groundbreaking inventions such as imidazolidinone compounds and methods to inhibit deubiquitination. The first patent features imidazolidinone compounds and pharmaceutical compositions that are utilized in treating deubiquitination-related disorders. These compounds are designed to inhibit p97-associated deubiquitination, providing a novel approach to treatment. His second patent discloses hydrazone and diacyl hydrazine compounds, which serve as inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. These derivatives are potent and selective inhibitors of the p97 ATPase, offering valuable tools for studying protein degradation and related processes.
Career Highlights
Trenkle's career is marked by his dedication to advancing pharmaceutical science. He works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His innovative research has the potential to impact the treatment of various diseases and disorders.
Collaborations
Throughout his career, Trenkle has collaborated with esteemed colleagues such as Adrian U Wiestner and Yihong Ye. These partnerships have contributed to the development of his patents and the advancement of research in his field.
Conclusion
William Trenkle is a distinguished inventor whose work in pharmaceutical compounds has the potential to revolutionize treatment methods for deubiquitination-related disorders. His contributions to science and medicine are noteworthy and continue to inspire future innovations.